Shilajit D Kundu1, Darren R Feldman2, Brett S Carver2, Amit Gupta3, George J Bosl2, Robert J Motzer2, Dean F Bajorin2, Joel Sheinfeld4. 1. Department of Urology, Northwestern Medicine, Chicago, Illinois. 2. Urology Service, Department of Surgery, and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Urology, University of Iowa Carver College of Medicine, Iowa City, Iowa. 4. Urology Service, Department of Surgery, and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: sheinfej@mskcc.org.
Abstract
PURPOSE: Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3). We report the histological results at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy in patients treated with etoposide and cisplatin or bleomycin, etoposide and cisplatin for good risk nonseminomatous germ cell tumors. MATERIALS AND METHODS: Post-chemotherapy retroperitoneal lymph node dissection was performed in 579 patients after induction chemotherapy. Of these patients 505 were treated with EPx4 and 74 were treated with BEPx3 or BEPx4. Clinical and pathological features are reported. RESULTS: No difference in the frequency of viable residual cancer was observed with bleomycin, etoposide and cisplatin vs etoposide and cisplatin (5% vs 6%, respectively, p=not significant). Teratoma was more prevalent in the bleomycin, etoposide and cisplatin group vs etoposide and cisplatin group (57% vs 34%, respectively, p <0.001). On multivariate analysis patients who received induction bleomycin, etoposide and cisplatin had a twofold greater risk of harboring teratoma at post-chemotherapy retroperitoneal lymph node dissection (OR 2.0; 95% CI 1.0, 4.0; p=0.04). When excluding patients from analysis who received BEPx4, those who received BEPx3 still had a 3.7-fold increased risk of teratoma in the retroperitoneum (OR 3.7; 95% CI 1.5, 8.9; p=0.004). Relapse-free and disease specific survival was not different between the 2 regimens. CONCLUSIONS: Viable cancer was equally uncommon after treatment with both regimens. Overall, relapse-free and disease specific survival did not differ between the groups. The discrepancy between regimens in the frequency of teratoma is not explained but may be due to an unrecognized selection bias rather than an effect of the regimen.
PURPOSE:Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3). We report the histological results at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy in patients treated with etoposide and cisplatin or bleomycin, etoposide and cisplatin for good risk nonseminomatous germ cell tumors. MATERIALS AND METHODS: Post-chemotherapy retroperitoneal lymph node dissection was performed in 579 patients after induction chemotherapy. Of these patients 505 were treated with EPx4 and 74 were treated with BEPx3 or BEPx4. Clinical and pathological features are reported. RESULTS: No difference in the frequency of viable residual cancer was observed with bleomycin, etoposide and cisplatin vs etoposide and cisplatin (5% vs 6%, respectively, p=not significant). Teratoma was more prevalent in the bleomycin, etoposide and cisplatin group vs etoposide and cisplatin group (57% vs 34%, respectively, p <0.001). On multivariate analysis patients who received induction bleomycin, etoposide and cisplatin had a twofold greater risk of harboring teratoma at post-chemotherapy retroperitoneal lymph node dissection (OR 2.0; 95% CI 1.0, 4.0; p=0.04). When excluding patients from analysis who received BEPx4, those who received BEPx3 still had a 3.7-fold increased risk of teratoma in the retroperitoneum (OR 3.7; 95% CI 1.5, 8.9; p=0.004). Relapse-free and disease specific survival was not different between the 2 regimens. CONCLUSIONS: Viable cancer was equally uncommon after treatment with both regimens. Overall, relapse-free and disease specific survival did not differ between the groups. The discrepancy between regimens in the frequency of teratoma is not explained but may be due to an unrecognized selection bias rather than an effect of the regimen.
Authors: G Varuni Kondagunta; Jennifer Bacik; Dean Bajorin; Deborah Dobrzynski; Joel Sheinfeld; Robert J Motzer; George J Bosl Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: R de Wit; J T Roberts; P M Wilkinson; P H de Mulder; G M Mead; S D Fosså; P Cook; L de Prijck; S Stenning; L Collette Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: G C Toner; M R Stockler; M J Boyer; M Jones; D B Thomson; V J Harvey; I N Olver; H Dhillon; A McMullen; V J Gebski; J A Levi; R J Simes Journal: Lancet Date: 2001-03-10 Impact factor: 79.321
Authors: Yaron Ehrlich; Mary J Brames; Stephen D W Beck; Richard S Foster; Lawrence H Einhorn Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: G C Toner; D M Panicek; R T Heelan; N L Geller; S Y Lin; D Bajorin; R J Motzer; H I Scher; H W Herr; M J Morse Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544
Authors: D F Bajorin; M F Sarosdy; D G Pfister; M Mazumdar; R J Motzer; H I Scher; N L Geller; W R Fair; H Herr; P Sogani Journal: J Clin Oncol Date: 1993-04 Impact factor: 44.544
Authors: Stephen D W Beck; Richard S Foster; Richard Bihrle; Thomas Ulbright; Michael O Koch; Gregory R Wahle; Lawrence H Einhorn; John P Donohue Journal: J Urol Date: 2002-10 Impact factor: 7.450
Authors: G J Bosl; N L Geller; D Bajorin; S P Leitner; A Yagoda; R B Golbey; H Scher; N J Vogelzang; J Auman; R Carey Journal: J Clin Oncol Date: 1988-08 Impact factor: 44.544
Authors: C-H Ohlmann; P Albers; K Boehm; M Graefen; O W Hakenberg; M Kuczyk; J Graf; I Peters; C Protzel Journal: Urologe A Date: 2015-09 Impact factor: 0.639
Authors: Samuel A Funt; Deaglan J McHugh; Stephanie Tsai; Andrea Knezevic; Devon O'Donnell; Sujata Patil; Deborah Silber; Maria Bromberg; Maryann Carousso; Victor E Reuter; Brett S Carver; Joel Sheinfeld; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman Journal: Oncologist Date: 2021-03-12
Authors: Daniel E Spratt; Krithika Suresh; Takahiro Osawa; Matthew Schipper; William C Jackson; Ahmed Abugharib; Amir Lebastchi; David Smith; Jeffrey S Montgomery; Ganesh S Palapattu; L Priya Kunju; Angela Wu; Madelyn Lew; Scott A Tomlins; Arul M Chinnaiyan; Alon Z Weizer; Khaled S Hafez; Samuel D Kaffenberger; Aaron Udager; Rohit Mehra Journal: Med Oncol Date: 2018-01-31 Impact factor: 3.064